Back to Search
Start Over
Clearance of buprenorphine during pregnancy and neonatal outcomes
- Source :
- Archives of Women's Mental Health. 24:933-939
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Buprenorphine is emerging as the preferred pharmacologic treatment for opioid use disorder during pregnancy. We examined the relative plasma clearance of buprenorphine (BUP) across pregnancy. Pregnant women with opioid use disorder participating in a prospective, observational study from 2013 to 2016 on stress in pregnancy who were receiving BUP for opioid use disorder were included. Women with an active eating disorder or suicidal ideation were excluded. Research visits occurred at 4–6-week intervals across pregnancy and the early postpartum period and included medication exposure history and blood samples. All assays for BUP serum concentrations at steady state were completed. Relative weight-adjusted clearance (Cl) was calculated using Cl = (daily dose [mg]/ body weight [kg])/serum concentration [ng/ml]. We collected 112 maternal blood samples from 29 women throughout pregnancy and the postpartum period. Serum concentrations for BUP ranged from
- Subjects :
- Pregnancy
medicine.medical_specialty
Dose
Obstetrics
business.industry
Obstetrics and Gynecology
Opioid use disorder
medicine.disease
030226 pharmacology & pharmacy
03 medical and health sciences
Psychiatry and Mental health
0302 clinical medicine
Neonatal outcomes
medicine
Gestation
030212 general & internal medicine
medicine.symptom
business
Suicidal ideation
Postpartum period
Buprenorphine
medicine.drug
Subjects
Details
- ISSN :
- 14351102 and 14341816
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- Archives of Women's Mental Health
- Accession number :
- edsair.doi...........04737d1e37a3bde06284e68e89953f1e